Inmedix Named a ‘Top Innovator’ at the 2017 New England Venture Summit

Share Article

Within rheumatology, Inmedix continues to define the new medical concept of immuno-autonomics

Inmedix, the leader in elite heart rate variability (HRV) application as an informative diagnostic tool for rheumatoid arthritis (RA) and other autoimmune diseases, was named a ‘Top Innovator’ at the 2017 New England Venture Summit in Boston Randolph.

The 12th annual New England Venture Summit, presented by youngStartup Ventures, is the premier industry gathering connecting venture capitalists, corporate VCs, angel investors, technology transfer professionals, senior executives of early stage and emerging growth companies, university researchers, incubators and premier service providers.

Among 144 participating companies, Inmedix continued to define the new medical concept of immuno-autonomics, where fight-or-flight stress – modulated within the brain by the autonomic nervous system (ANS) – collides with the immune system to drive autoimmune disease to excess.

“Our commitment at this summit is to help light the way, providing industry insight, essential connections, and introducing Top Innovators to value-added investors,” explains Joe Benjamin, Founder & CEO of youngStartup Ventures, Inc.

In a prospective, double-blinded, clinical trial of 33 patients, Inmedix has reported how ANS state, as measured by its immuno-autonomic diagnostic, the ANS Neuroscan™ prototype, predicted RA biologic treatment response at 52-weeks with 90% sensitivity and 95.7% specificity (1,2). For immuno-autonomic therapeutics, a number of academics and commercial entities, including Inmedix (3), have reported how optimizing ANS state may reduce disease severity and/or improve treatment outcome for patients with RA. HRV measures of ANS dysregulation have also been found to precede the onset of RA (4). Consequently, assessing and optimizing ANS state has become a research focus not only to improve traditional immunosuppressive outcomes for patients with RA, but to also establish a pathway toward disease prevention.

“Our team is profoundly grateful for this recognition,” said Andrew J. Holman, MD, Inmedix CEO and Clinical Associate Professor of Medicine at the University of Washington. “We remain determined to help patients with autoimmune diseases get their lives back.”

About Inmedix, LLC
Seattle-based biotech Inmedix is committed to engaging in world class research to discover innovative solutions for pressing healthcare needs related to the autonomic nervous system (ANS). Inmedix’s ANS Neuroscan is the leading heart rate variability (HRV) application as an informative diagnostic tool in autoimmune disease, beginning with patients with rheumatoid arthritis (RA). The company’s science and technology hope to raise therapeutic outcomes so that patients will no longer need to cycle through failure of one therapeutic intervention after another. For more information, visit

1. Holman AJ, Ng E. Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis. Autonomic Neurosci: Basic Clin 2008;143:58-67.
2. Holman AJ, Ng E. How substantive is heart rate variability as a predictor of anti-TNF treatment outcome for inflammatory arthritis? [abstract] Arthritis Rheumatol. 2015;67 (suppl 10)
3. Holman AJ, Ng E. Use of adjunctive neuroregulatory medication to improve etanercept treatment response for patients with inflammatory arthritis a pilot study [abstract]. Arthritis Rheumatol. 2015;67 (suppl 10).
4. Koopman FA, Tang MW, Vermeij J, Choi IY, Vervoordeldonk MJ, Gerlag DM, Karemaker JM, Tak PP. Autonomic dysfunction precedes development of rheumatoid arthritis: a prospective cohort study. EBioMedicine 2016;6:231-237.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rae Marie Gleason

+1 714-423-4863
Email >
Visit website